Cytokinetics Inc
$ 66.54
2.91%
04 Dec - close price
- Market Cap 7,905,651,000 USD
- Current Price $ 66.54
- High / Low $ 67.26 / 63.50
- Stock P/E N/A
- Book Value -4.26
- EPS -6.30
- Next Earning Report 2026-03-04
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.25 %
- ROE -5.72 %
- 52 Week High 69.33
- 52 Week Low 29.31
About
Cytokinetics, Incorporated is a clinical-stage biopharmaceutical company based in South San Francisco, California, specializing in the development of innovative therapies for muscle-related diseases, notably heart failure and various neuromuscular disorders. Leveraging its expertise in muscle biology, the company is advancing a promising pipeline of muscle activators and inhibitors that aim to significantly improve patient outcomes. Cytokinetics' commitment to scientific innovation and its strategic focus on unmet medical needs position it as a potential leader in the biopharmaceutical sector, drawing the attention of institutional investors seeking groundbreaking healthcare solutions.
Analyst Target Price
$79.56
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-05 | 2025-08-07 | 2025-05-06 | 2025-02-25 | 2024-11-06 | 2024-08-08 | 2024-05-08 | 2024-02-27 | 2023-11-02 | 2023-08-03 | 2023-05-04 | 2023-03-01 |
| Reported EPS | -2.55 | -1.12 | -1.36 | -1.26 | -1.36 | -1.31 | -1.33 | -1.38 | -1.35 | -1.34 | -1.38 | -1.45 |
| Estimated EPS | -1.57 | -1.42 | -1.3631 | -1.174 | -1.25 | -1.06 | -1.14 | -0.97 | -0.74 | -1.15 | -1.2 | -1.21 |
| Surprise | -0.98 | 0.3 | 0.0031 | -0.086 | -0.11 | -0.25 | -0.19 | -0.41 | -0.61 | -0.19 | -0.18 | -0.24 |
| Surprise Percentage | -62.4204% | 21.1268% | 0.2274% | -7.3254% | -8.8% | -23.5849% | -16.6667% | -42.268% | -82.4324% | -16.5217% | -15% | -19.8347% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-04 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -1.41 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CYTK
2025-10-31 15:42:00
The Rosen Law Firm is reminding investors who purchased Cytokinetics, Inc. (NASDAQ: CYTK) common stock between December 27, 2023, and May 6, 2025, of the upcoming November 17, 2025, lead plaintiff deadline for a securities class action lawsuit. The lawsuit alleges that Cytokinetics made false and misleading statements regarding the New Drug Application (NDA) submission and approval timeline for its drug aficamten, specifically concerning an undisclosed failure to submit a Risk Evaluation and Mitigation Strategy (REMS). Investors who suffered damages are encouraged to join the class action.
2025-10-30 13:43:00
Glancy Prongay & Murray LLP is reminding investors of Cytokinetics, Incorporated (NASDAQ: CYTK) about a November 17, 2025, deadline to file a lead plaintiff motion in a class action lawsuit. This lawsuit alleges securities fraud due to the company's failure to disclose crucial information regarding the submission of their NDA for aficamten without an accompanying Risk Evaluation and Mitigation Strategy (REMS), leading to a three-month delay in FDA review and subsequent stock price drops. Investors who suffered losses during the Class Period (December 27, 2023, to May 6, 2025) are urged to contact the law firm.
2025-10-28 16:31:00
Cytokinetics, a late-stage biopharma company specializing in heart diseases, has seen its shares jump significantly due to strong phase 3 trial results for its drug, Aficamten. This drug is poised to compete with Bristol Myers Squibb's offering, which was originally discovered by Cytokinetics. The company is actively pursuing FDA approval for Aficamten and is supported by diverse funding strategies.
2025-10-22 00:00:00
Cytokinetics announced it will report its third-quarter 2025 financial results on November 5, 2025, at 4:00 PM Eastern Time, followed by a conference call at 4:30 PM Eastern Time. The call will discuss financial results and business updates, with a webcast available on their website. The company also provided an overview of its pipeline, including aficamten, omecamtiv mecarbil, ulacamten, and CK-089, which are investigational medicines for various cardiac muscle dysfunctions, currently awaiting regulatory approval.
2025-10-18 20:03:05
Pomerantz LLP has filed a class action lawsuit against Cytokinetics for securities fraud, with investors having until November 17, 2025, to apply for Lead Plaintiff status. Additionally, Cytokinetics announced inducement grants in accordance with Nasdaq Listing Rule 5635(C)(4).
2025-10-17 23:02:38
Rosen Law Firm is encouraging investors of Cytokinetics, Inc. (NASDAQ: CYTK) who purchased stock between December 27, 2023, and May 6, 2025, to secure counsel before the lead plaintiff deadline of November 17, 2025, in a securities class action. The lawsuit alleges that Cytokinetics made misleading statements regarding the timeline for FDA approval of its drug aficamten, specifically failing to disclose risks related to not submitting a Risk Evaluation and Mitigation Strategy (REMS). Investors who suffered damages due to these alleged misrepresentations may be entitled to compensation.
